All In Biotech

Drug Trial Radar · NCT03602261

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis.

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

44

Actual

Start

Jul 9, 2018

Primary completion

Feb 24, 2021

Study completion Feb 24, 2021

Sponsor

Lead sponsor
OPKO Health, Inc.Industry
Sponsor type
Industry
First posted
Jul 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI

Conditions

  • Secondary Hyperparathyroidism Due to Renal Causes
  • Chronic Kidney Diseases
  • Vitamin D Deficiency
  • Stage 5 Chronic Kidney Disease

Interventions

  • Calcifediol Oral CapsuleDrug

    Capsule, weekly

  • Placebo oral capsuleDrug

    Capsule, weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Response During Efficacy Assessment PeriodTime frame: 26 weeks
  2. Total 25-hydroxyvitamin D Response Analysis During Efficacy PeriodTime frame: 26 weeks
  3. Number of Participants With Intact Parathyroid Hormone (iPTH) Response During Efficacy Assessment PeriodTime frame: 26 weeks
  4. Pharmacokinetic (PK) Profile (Cmax) of Serum CalcifediolTime frame: 0, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48 hours post-dose (single and repeat dose)
  5. Pharmacokinetic (PK) Profile (Tmax) of Serum CalcifediolTime frame: 0, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48 hours post-dose (single and repeat dose)
  6. Pharmacokinetic (PK) Profile (AUC0-t) of Serum CalcifediolTime frame: 0, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48 hours post-dose (single and repeat dose)

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • AKDHC Medical Research Services

    Peoria, Arizona

  • AKDHC Medical Research Services

    Phoenix, Arizona

  • AKDHC Medical Research Services

    Phoenix, Arizona

  • AKDHC Medical Research Services

    Phoenix, Arizona

  • WCCT Global, Inc.

    Cypress, California

  • Hacienda Dialysis Center

    Hacienda Heights, California

  • California Institute of Renal Research CKD/Dialysis & Transplant Division

    La Mesa, California

  • Long Beach Quest Dialysis Center

    Long Beach, California

  • Ontario Dialysis Center

    Ontario, California

  • North America Research Institute, Inc.

    San Dimas, California

  • Laurel Canyon Dialysis, LLC

    Sun Valley, California

  • University of Colorado Denver Anschutz Medical Campus

    Aurora, Colorado

  • Research by Design, LLC

    Chicago, Illinois

  • Northshore University Health

    Evanston, Illinois

  • Renal and Transplant Associates of New England

    Springfield, Massachusetts

  • Southwest MS Nephrology

    McComb, Mississippi

  • Southwest Houston Research LTD

    Houston, Texas

  • Kidney & Hypertension Specialists

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.